Search

Your search keyword '"MESH: Congresses as Topic"' showing total 9 results
Start Over Descriptor "MESH: Congresses as Topic" Topic business
9 results on '"MESH: Congresses as Topic"'

1. Establishment of Asia-Pacific Network for Enterovirus Surveillance

Author

Ya-Yen Chen, Yoke Fun Chan, Veasna Duong, Wan Yu Chung, Shu Ting Luo, Philippe Dussart, Huu Khanh Truong, Mu-Lin Chiu, Nguyen Thi Thanh Thao, Mong How Ooi, David Perera, Min-Shi Lee, National Health Research Institutes [Taiwan] (NHRI), Unité de Virologie / Virology Unit [Phnom Penh], Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), University of Malaya [Kuala Lumpur, Malaisie], Universiti Malaysia Sarawak (UNIMAS), Sarawak General Hospital [Kuching, Sarawak, Malaysia], Institut Pasteur d'Ho Chi Minh Ville, Réseau International des Instituts Pasteur (RIIP), Children's Hospital No.1 [Ho Chi Minh City], and This project is partialy funded by National Flagship Project, Taiwan (MOST 106-3114-Y404-002).

Subjects
Echovirus, viruses, Disease, medicine.disease_cause, 0302 clinical medicine, 030212 general & internal medicine, MESH: Hand, Foot and Mouth Disease, Enterovirus, biology, MESH: Asia, MESH: Enterovirus Infections, 3. Good health, Infectious Diseases, MESH: Enterovirus A, Human, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, MESH: Sentinel Surveillance, Molecular Medicine, Asia, 030231 tropical medicine, Taiwan, Coxsackievirus, Herpangina, 03 medical and health sciences, MESH: Viral Vaccines, Environmental health, medicine, Enterovirus Infections, Humans, MESH: Taiwan, MESH: Pacific Ocean, Disease burden, Licensure, MESH: Humans, Pacific Ocean, General Veterinary, General Immunology and Microbiology, business.industry, Public Health, Environmental and Occupational Health, Outbreak, Viral Vaccines, Congresses as Topic, biology.organism_classification, medicine.disease, Enterovirus A, Human, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Hand, Foot and Mouth Disease, Vaccine, Sentinel Surveillance, Asia-Pacific region, MESH: Congresses as Topic
Abstract

International audience; Enteroviruses (EV), the major pathogens of hand, foot, and mouth disease (HFMD) and herpangina, affect millions of children each year. Most human enteroviruses cause self-limited infections except polioviruses, enterovirus A71 (EV-A71), enterovirus D68 (EV-D68), and several echoviruses (Echo) and coxsackieviruses (CV). Especially, EV-A71 has repeatedly caused large-scale outbreaks in the Asia-Pacific region since 1997. Some Asian countries have experienced cyclical outbreaks of severe EV-A71 infections and initiated development of EV-A71 vaccines. Five EV-A71 vaccine candidates have been clinically evaluated and three of them were approved for marketing in China. However, none of the China-approved products seek marketing approval in other countries. This situation supports a role for collaboration among Asian countries to facilitate clinical trials and licensure of EV-A71 vaccines. Additionally, enterovirus D68 outbreaks have been reported in the US and Taiwan currently and caused severe complications and deaths. Hence, an Asia-Pacific Network for Enterovirus Surveillance (APNES) has been established to estimate disease burden, understand virus evolution, and facilitate vaccine development through harmonizing laboratory diagnosis and data collection. Founded in 2017, the APNES is comprised of internationally recognized experts in the field of enterovirus in Asian countries working to raise awareness of this potentially fatal and debilitating disease. This article demonstrated the summaries of the first expert meeting, 2017 International Workshop on Enterovirus Surveillance and Vaccine Development, held by APNES in Taipei, Taiwan, March 2017.

Published
2019
Full Text
View/download PDF

2. CRISPR in Parasitology: Not Exactly Cut and Dried!

Author

Jessica M. Bryant, Sebastian Baumgarten, Lucy Glover, Sebastian Hutchinson, Najma Rachidi, Biologie des Interactions Hôte-Parasite - Biology of Host-Parasite Interactions, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Biologie moléculaire des Trypanosomes - Trypanosome Molecular Biology, Institut Pasteur [Paris] (IP), Biologie cellulaire des Trypanosomes - Trypanosome Cell Biology, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Parasitologie moléculaire et Signalisation / Molecular Parasitology and Signaling, S.B. was supported by a European Molecular Biology Organization long-term postdoctoral fellowship (EMBO LTF 1444-2016). S.H. was supported by a Roux postdoctoral fellowship from the Institut Pasteur. N.R. was supported by grant ANR-13-ISV3-0009 and the LabEx IBEID., ANR-13-ISV3-0009,TranSig,Trans-signalisation: Un nouveau mécanisme permettant à Leishmania d'éviter la réponse immunitaire de la cellule hôte par la sécrétion de protéines de signalisation(2013), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Rachidi, Najma, Blanc – Accords bilatéraux 2013 - Trans-signalisation: Un nouveau mécanisme permettant à Leishmania d'éviter la réponse immunitaire de la cellule hôte par la sécrétion de protéines de signalisation - - TranSig2013 - ANR-13-ISV3-0009 - Blanc – Accords bilatéraux 2013 - VALID, and Integrative Biology of Emerging Infectious Diseases - - IBEID2010 - ANR-10-LABX-0062 - LABX - VALID

Subjects
0301 basic medicine, Engineering, Plasmodium, Trypanosoma, MESH: CRISPR-Cas Systems, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, 030231 tropical medicine, MESH: Parasitology, Computational biology, 03 medical and health sciences, 0302 clinical medicine, Anopheles, CRISPR, Animals, Humans, Parasites, MESH: Animals, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, MESH: Parasites, Leishmania, MESH: Humans, business.industry, Cas9, Research, CRISPRi, Congresses as Topic, [SDV.BIO] Life Sciences [q-bio]/Biotechnology, 3. Good health, 030104 developmental biology, Infectious Diseases, MESH: Research, Parasitology, CRISPR-Cas Systems, business, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, MESH: Congresses as Topic
Abstract

International audience; CRISPR/Cas9 technology has been developing rapidly in the field of parasitology, allowing for the dissection of molecular processes with unprecedented efficiency. Optimization and implementation of a new technology like CRISPR, especially in nonmodel organisms, requires communication and collaboration throughout the field. Recently, a 'CRISPR in Parasitology' symposium was held at the Institut Pasteur Paris, bringing together scientists studying Leishmania, Plasmodium, Trypanosoma, and Anopheles. Here we share technological advances and challenges in using CRISPR/Cas9 in the parasite and vector systems that were discussed. As CRISPR/Cas9 continues to be applied to diverse parasite systems, the community should now focus on improvement and standardization of the technique as well as expanding the CRISPR toolkit to include Cas9 alternatives/derivatives for more advanced applications like genome-wide functional screens.

Published
2019
Full Text
View/download PDF

3. Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017

Author

Michelle A. Lowes, Mayur Ramesh, Gregory S. Schultz, Vincent Piguet, Aude Nassif, Haley B. Naik, Afsaneh Alavi, University of California [San Francisco] (UCSF), University of California, Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris], Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Toronto, Rockefeller University [New York], University of California [San Francisco] (UC San Francisco), University of California (UC), Institut Pasteur [Paris] (IP), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], and Centre Médical de l'Institut Pasteur

Subjects
0301 basic medicine, [SDV]Life Sciences [q-bio], Dermatology, MESH: Hidradenitis Suppurativa, Biochemistry, Article, 03 medical and health sciences, 0302 clinical medicine, MESH: Microbiota, Medicine, Humans, Hidradenitis suppurativa, Molecular Biology, Retrospective Studies, MESH: Humans, biology, Bacteria, business.industry, Microbiota, MESH: Retrospective Studies, Cell Biology, Congresses as Topic, medicine.disease, biology.organism_classification, Hidradenitis Suppurativa, MESH: Bacteria, 030104 developmental biology, Infectious disease (medical specialty), 030220 oncology & carcinogenesis, Immunology, business, MESH: Congresses as Topic, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

Meeting held at Henry Ford Hospital, Detroit, Michigan, in November 2017; International audience; In November 2017, a formal debate on the role of bacteria in the pathogenesis of hidradenitis suppurativa (HS) was held at the 2nd Symposium on Hidradenitis Suppurativa Advances (SHSA) in Detroit, Michigan. In this report, we present both sides of the argument as debated at the SHSA meeting and then discuss the potential role of bacteria as classic infectious pathogens versus an alternative pathogenic role as activators of dysregulated commensal bacterial-host interactions. Although there was consensus that bacteria play a role in pathogenesis and thus are pathogenic, there was a compelling discussion about whether bacteria in HS incite an infectious disease as we classically understand it or whether bacteria might play a different role in HS pathogenesis.

Published
2018
Full Text
View/download PDF

4. 1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15–16 November 2016, Evry, France

Author

Justine Marsolier, Pascal Laforet, Elena Pegoraro, John Vissing, Isabelle Richard, Christine Barnerias, Robert-Yves Carlier, Jordi Díaz-Manera, Abdallah Fayssoil, Anne Galy, Elisabetta Gazzerro, Dariusz Górecki, Michela Guglieri, Jean-Yves Hogrel, David Israeli, France Leturcq, Helene Moussu, Helene Prigent, Dorianna Sandona, Benedikt Schoser, Claudio Semplicini, Beril Talim, Giorgio Tasca, Andoni Urtizberea, Bjarne Udd, Université Paris-Saclay, Institut de Myologie, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Association française contre les myopathies (AFM-Téléthon)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Pierre et Marie Curie - Paris 6 (UPMC), Universita degli Studi di Padova, University of Copenhagen = Københavns Universitet (KU), Approches génétiques intégrées et nouvelles thérapies pour les maladies rares (INTEGRARE), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Généthon, Service de neurologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Imagerie Médicale [Raymond-Poincaré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Raymond Poincaré [AP-HP], CIBER de Enfermedades Raras (CIBERER), Généthon, Institute of Human Genetics, Newcastle University [Newcastle]-International Centre for Life, Hôpital Cochin [AP-HP], Groupe de Recherche Clinique et Technologique sur le Handicap (GRCTH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Medical Genetics and Pediatric Cardiology, IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Association française contre les myopathies (AFM-Téléthon), Neurology Department, Université Pierre et Marie Curie - Paris 6 (UPMC)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Généthon-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Hôpital Raymond Poincaré [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), École pratique des hautes études (EPHE)-Université d'Évry-Val-d'Essonne (UEVE)-GENETHON 3-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service d'Imagerie Médicale [CHU Raymond Poincaré], AP-HP Hôpital Raymond Poincaré [Garches]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), CHU Cochin [AP-HP], Università degli Studi di Padova = University of Padua (Unipd), University of Copenhagen = Københavns Universitet (UCPH), and École Pratique des Hautes Études (EPHE)

Subjects
0301 basic medicine, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, Clinical presentation, International Cooperation, Treatment outcome, Natural history, Clinical presentation, Pathogenic mechanism, Outcome measures, Biomarkers, Animal models of sarcoglycanopathies,Therapies, Outcome measures, MESH: Magnetic Resonance Imaging, Pathogenic mechanism, 0302 clinical medicine, Environmental protection, Medicine, Genetics (clinical), ComputingMilieux_MISCELLANEOUS, MESH: Treatment Outcome, Clinical Trials as Topic, MESH: Muscle, Skeletal, MESH: Sarcoglycanopathies, Animal models of sarcoglycanopathies, Magnetic Resonance Imaging, 3. Good health, Treatment Outcome, Neurology, France, Sarcoglycanopathies, medicine.medical_specialty, MESH: Clinical Trials as Topic, Natural history, MEDLINE, 03 medical and health sciences, Humans, Medical physics, Muscle, Skeletal, MESH: Humans, business.industry, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Congresses as Topic, Clinical trial, MESH: France, MESH: International Cooperation, 030104 developmental biology, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Therapies, Pediatrics, Perinatology and Child Health, Neurology (clinical), business, Biomarkers, 030217 neurology & neurosurgery, MESH: Congresses as Topic
Abstract

• The present ENMC workshop report summarises the current state of clinical readiness for sarcoglycanopathies.

Published
2017
Full Text
View/download PDF

5. 219th ENMC International Workshop Titinopathies International database of titin mutations and phenotypes, Heemskerk, The Netherlands, 29 April–1 May 2016

Author

Peter Hackman, Bjarne Udd, Carsten G. Bönnemann, Ana Ferreiro, Carsten Bonnemann, Alan Beggs, Mathias Gautel, Mark Davis, Teresinha Evangelista, Marco Savarese, Jelena Nikodinovic Glumac, Jocelyn Laporte, John Edward Smith, Isabelle Richard, Henk Granzier, Raphäel Schneider, Heinz Jungbluth, Sarah Foye, Alison Rockett Frase, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, University of Tampere [Finland], National Institute of Neurological Disorders and Stroke [Bethesda] (NINDS), National Institutes of Health [Bethesda] (NIH), Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Titinopathy Database Consortium: Bjarne Udd , Peter Hackman , Ana Ferreiro , Carsten Bonnemann , Alan Beggs , Mathias Gautel , Mark Davis , Teresinha Evangelista , Marco Savarese , Jelena Nikodinovic Glumac , Jocelyn Laporte , John Edward Smith , Isabelle Richard , Henk Granzier , Raphäel Schneider , Heinz Jungbluth , Sarah Foye , Alison Rockett Frase, Richard, Isabelle, Haartman Institute [Helsinki], Faculty of Medecine [Helsinki], University of Helsinki-University of Helsinki, Neurology Department, Physiopathologie et thérapie du muscle strié, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-Institut National de la Santé et de la Recherche Médicale (INSERM), Boston Children's Hospital, University of East London & Glasgow Caledonian University, Institut de génétique et biologie moléculaire et cellulaire (IGBMC), Université Louis Pasteur - Strasbourg I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Approches génétiques intégrées et nouvelles thérapies pour les maladies rares (INTEGRARE), École pratique des hautes études (EPHE)-Université d'Évry-Val-d'Essonne (UEVE)-GENETHON 3-Institut National de la Santé et de la Recherche Médicale (INSERM), Washington State University (WSU), Laboratoire Réactions et Génie des Procédés (LRGP), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Department of Paediatric Neurology, Guy's and St Thomas' Hospital [London]-Evelina Children's Hospital, Helsingin yliopisto = Helsingfors universitet = University of Helsinki-Helsingin yliopisto = Helsingfors universitet = University of Helsinki, École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Généthon, Guy's and St Thomas' Hospital [London]-Evelina London Children's Hospital, Medicum, Department of Medical and Clinical Genetics, and Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Louis Pasteur - Strasbourg I

Subjects
0301 basic medicine, MESH: Connectin, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, International Cooperation, Bioinformatics, [SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, 0302 clinical medicine, Connectin, C-TERMINAL TITIN, Genetics (clinical), ComputingMilieux_MISCELLANEOUS, Netherlands, biology, MUSCLE INVOLVEMENT, Dilated cardiomyopathy, Phenotype, Early respiratory failure, Neurology, Titin, COMMON-CAUSE, TTN, MESH: Mutation, education, MEDLINE, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, 03 medical and health sciences, Muscular Diseases, Tibial Muscular Dystrophy, International database, DISTAL MYOPATHY, medicine, HEREDITARY MYOPATHY, Humans, TRUNCATING MUTATIONS, TIBIAL MUSCULAR-DYSTROPHY, EARLY RESPIRATORY-FAILURE, MESH: Humans, business.industry, MESH: Muscular Diseases, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Congresses as Topic, medicine.disease, DILATED CARDIOMYOPATHY, [SDV.BIO] Life Sciences [q-bio]/Biotechnology, MESH: International Cooperation, 030104 developmental biology, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Mutation, Pediatrics, Perinatology and Child Health, MESH: Netherlands, biology.protein, Neurology (clinical), 3111 Biomedicine, business, 030217 neurology & neurosurgery, MESH: Congresses as Topic
Abstract

International audience; No abstract available

Published
2017
Full Text
View/download PDF

6. Dyspnoea: a multidimensional and multidisciplinary approach

Author

Lionel Naccache, Valerie Bougault, Lee Romer, Hans-Joachim Kabitz, Päivi Piirilä, Mark Parshall, Sorbonne Université (SU), Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Université Laval [Québec] (ULaval), Neurophysiologie Respiratoire Expérimentale et Clinique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), INSERM U999, Laboratoire Motricité Humaine Expertise Sport Santé (LAMHESS), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université de Toulon (UTLN)-Université Côte d'Azur (UCA), Bougault, Valérie, Neurophysiologie Respiratoire Expérimentale et Clinique (UMRS 1158), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Université Nice Sophia Antipolis (1965 - 2019) (UNS)

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, MESH: Exercise Tolerance, Heart disease, [SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Health Status, Pulmonary disease, MESH: Pulmonary Disease, Chronic Obstructive, Disease, Angina, Pulmonary Disease, Chronic Obstructive, Quality of life, Multidisciplinary approach, medicine, Pulmonary Medicine, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, [SDV.EE.SANT] Life Sciences [q-bio]/Ecology, environment/Health, Exercise, MESH: Pulmonary Medicine, MESH: Health Status, MESH: Treatment Outcome, MESH: Respiration, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, COPD, Exercise Tolerance, MESH: Humans, business.industry, Respiration, Interstitial lung disease, Congresses as Topic, medicine.disease, 3. Good health, respiratory tract diseases, MESH: France, Dyspnea, Treatment Outcome, MESH: Dyspnea, MESH: Exercise, Physical therapy, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], France, business, MESH: Congresses as Topic
Abstract

Item does not contain fulltext Dyspnoea is a debilitating symptom that affects quality of life, exercise tolerance and mortality in various disease conditions/states. In patients with chronic obstructive pulmonary disease (COPD), it has been shown to be a better predictor of mortality than forced expiratory volume in 1 s. In patients with heart disease it is a better predictor of mortality than angina. Dyspnoea is also associated with decreased functional status and worse psychological health in older individuals living at home. It also contributes to the low adherence to exercise training programmes in sedentary adults and in COPD patients. The mechanisms of dyspnoea are still unclear. Recent studies have emphasised the multidimensional nature of dyspnoea in the sensory-perceptual (intensity and quality), affective distress and impact domains. The perception of dyspnoea involves a complex chain of events that depend on varying cortical integration of several afferent/efferent signals and coloured by affective processing. This review, which stems from the European Respiratory Society research symposium held in Paris, France in November 2012, aims to provide state-of-the-art advances on the multidimensional and multidisciplinary aspects of dyspnoea, by addressing three different themes: 1) the neurophysiology of dyspnoea, 2) exercise and dyspnoea, and 3) the clinical impact and management of dyspnoea.

Published
2014
Full Text
View/download PDF

7. Adrenal cancer: scientific advances

Author

Gary D. Hammer, Martin Fassnacht, Enzo Lalli, University of Michigan [Ann Arbor], University of Michigan System, Comprehensive Heart Failure Center, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU)-University Hospital of Würzburg-Rudolf Virchow Center for Experimental Biomedicine, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Institut de pharmacologie moléculaire et cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)

Subjects
0303 health sciences, MESH: Humans, business.industry, MESH: Biomedical Research, Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, medicine.disease, Bioinformatics, Biochemistry, MESH: Adrenal Gland Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Text mining, 030220 oncology & carcinogenesis, medicine, MESH: Animals, business, Molecular Biology, MESH: Germany, ComputingMilieux_MISCELLANEOUS, MESH: Congresses as Topic, 030304 developmental biology, MESH: Periodicals as Topic
Abstract

International audience

Published
2012
Full Text
View/download PDF

8. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia

Author

Stéphane Bretagne, Maurizio Sanguinetti, Paul Verweij, Janos Sinko, MALGORZATA MIKULSKA, Nikolay Klimko, Thierry Calandra, Frederic Lamoth, Malcolm Richardson, Daniel Poulain, Maiken Cavling Arendrup, Division of Infectious Diseases, San Martino University Hospital, nfectious Diseases Service, Université de Lausanne (UNIL)-Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Istituto di Microbiologia - Institute of Microbiology [Rome], Università cattolica del Sacro Cuore [Piacenza e Cremona] (Unicatt), Physiopathologie des Candidoses, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, University of Genoa (UNIGE)-San Martino University Hospital, the Third European Conference on Infections in Leukemia Group, Université de Lausanne = University of Lausanne (UNIL)-Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Università degli studi di Genova = University of Genoa (UniGe)-San Martino University Hospital, BMC, Ed., Third European Conference on Infections in Leukemia Group, Akova, M., Arendrup, M., Barnes, R., Bille, J., Bretagne, S., Calandra, T., Castagnola, E., Cordonnier, C., Cornely, OA., Cruciani, M., Cuenca-Estrella, M., Dannaoui, E., De La Camara, R., Dellow, E., Donnelly, P., Drgona, L., Einsele, H., Engelhard, D., Flückiger, U., Gachot, B., Gonzales-Moreno, J., Groll, A., Hanel, I., Herbrecht, R., Heussel, CP., Jones, B., Kibbler, C., Klimko, N., Klingspor, L., Kouba, M., Lamoth, F., Lanternier, F., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Maschan, A., Mikulska, M., Pagano, L., Petrikos, G., Poulain, D., Racil, Z., Reusser, P., Ribaud, P., Richardson, M., Rizzi-Puechal, V., Ruhnke, M., Sanguinetti, M., Sinko, J., Skiada, A., Styczynski, J., Thiebaut, A., Verweij, P., Viscoli, C., Wahl, J., Ward, K., and White, P.

Subjects
[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Critical Care and Intensive Care Medicine, Gastroenterology, Serology, law.invention, Mannans, 0302 clinical medicine, MESH: Practice Guidelines as Topic, law, Medicine, MESH: Animals, 030212 general & internal medicine, Candida, Randomized Controlled Trials as Topic, Mannan, 0303 health sciences, Leukemia, mannan, Intensive care unit, 3. Good health, Europe, Practice Guidelines as Topic, medicine.medical_specialty, Antigens, Fungal, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA, Animals, Antibodies, Fungal/biosynthesis, Antigens, Fungal/immunology, Candida/immunology, Candidiasis, Invasive/diagnosis, Candidiasis, Invasive/immunology, Congresses as Topic, Humans, Leukemia/complications, Leukemia/immunology, Mannans/immunology, Practice Guidelines as Topic/standards, Randomized Controlled Trials as Topic/standards, 03 medical and health sciences, MESH: Mannans, MESH: Candida, Internal medicine, MESH: Leukemia, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Candidiasis, Invasive, Antibodies, Fungal, MESH: Antigens, Fungal, MESH: Humans, 030306 microbiology, business.industry, Research, MESH: Antibodies, Fungal, Cancer, Odds ratio, medicine.disease, Confidence interval, MESH: Candidiasis, Invasive, MESH: Randomized Controlled Trials as Topic, Immunology, Diagnostic odds ratio, MESH: Europe, business, MESH: Congresses as Topic
Abstract

International audience; INTRODUCTION: Timely diagnosis of invasive candidiasis (IC) remains difficult as the clinical presentation is not specific and blood cultures lack sensitivity and need a long incubation time. Thus, non-culture-based methods for diagnosing IC have been developed. Mannan antigen (Mn) and anti-mannan antibodies (A-Mn) are present in patients with IC. On behalf of the Third European Conference on Infections in Leukemia, the performance of these tests was analysed and reviewed. METHODS: The literature was searched for studies using the commercially available sandwich enzyme-linked immunosorbent assays (Platelia™, Bio-Rad Laboratories, Marnes-la-Coquette, France) for detecting Mn and A-Mn in serum. The target condition of this review was IC defined according to 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. Sensitivity, specificity and diagnostic odds ratios (DOR) were calculated for Mn, A-Mn and combined Mn/A-Mn testing. RESULTS: Overall, 14 studies that comprised 453 patients and 767 controls were reviewed. The patient populations included in the studies were mainly haematological and cancer cases in seven studies and mainly intensive care unit and surgery cases in the other seven studies. All studies but one were retrospective in design. Mn sensitivity was 58% (95% confidence interval [CI], 53-62); specificity, 93% (95% CI, 91-94) and DOR, 18 (95% CI 12-28). A-Mn sensitivity was 59% (95% CI, 54-65); specificity, 83% (95% CI, 79-97) and DOR, 12 (95% CI 7-21). Combined Mn/A-Mn sensitivity was 83% (95% CI, 79-87); specificity, 86% (95% CI, 82-90) and DOR, 58 (95% CI 27-122). Significant heterogeneity of the studies was detected. The sensitivity of both Mn and A-Mn varied for different Candida species, and it was the highest for C. albicans, followed by C. glabrata and C. tropicalis. In 73% of 45 patients with candidemia, at least one of the serological tests was positive before the culture results, with mean time advantage being 6 days for Mn and 7 days for A-Mn. In 21 patients with hepatosplenic IC, 18 (86%) had Mn or A-Mn positive test results at a median of 16 days before radiological detection of liver or spleen lesions. CONCLUSIONS: Mn and A-Mn are useful for diagnosis of IC. The performance of combined Mn/A-Mn testing is superior to either Mn or A-Mn testing.

Published
2010
Full Text
View/download PDF

9. Imaging recommendations in paediatric uroradiology. Minutes of the ESPR uroradiology task force session on childhood obstructive uropathy, high-grade fetal hydronephrosis, childhood haematuria, and urolithiasis in childhood. ESPR Annual Congress, Edinburgh, UK, June 2008

Author

Johan G. Blickman, Michael Riccabona, Kassa Darge, Ulrich Willi, Jean-Nicholas Dacher, Fred E. Avni, Maria Luisa Lobo, Breton, Céline, Department of Radiology, University Hospital Graz, Department of Medical Imaging, University Clinics of Brussels, Radboud University Medical Center [Nijmegen], Service d'imagerie médicale [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Children’s Hospital of Philadelphia (CHOP ), Hospital de Santa Maria, Department of Radiology [Stanford], Stanford Medicine, Stanford University-Stanford University, Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen]-CHU Rouen

Subjects
Diagnostic Imaging, Urologic Diseases, Pediatrics, medicine.medical_specialty, Urology, Fetal hydronephrosis, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, MESH: Practice Guidelines as Topic, 030225 pediatrics, MESH: Child, Medical imaging, medicine, Humans, Radiology, Nuclear Medicine and imaging, Child, Obstructive uropathy, Hydronephrosis, ComputingMilieux_MISCELLANEOUS, Neuroradiology, [SDV.IB] Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, MESH: Humans, Task force, business.industry, MESH: Diagnostic Imaging, Congresses as Topic, medicine.disease, MESH: Urology, MESH: Urologic Diseases, 3. Good health, Europe, Imaging algorithm, Practice Guidelines as Topic, Pediatrics, Perinatology and Child Health, MESH: Pediatrics, Urologic disease, [SDV.IB]Life Sciences [q-bio]/Bioengineering, MESH: Europe, MESH: Radiology, Radiology, business, MESH: Congresses as Topic
Abstract

The imaging and procedural recommendations as elaborated by the ESPR Paediatric Uroradiology Taskforce and the ESUR Paediatric Uroradiology Working Group were presented and discussed at the first uroradiology panel held during the ESPR Annual Congress in Barcelona in 2007. These recommendations were published in this journal [1] and have gained wide acceptance throughout Europe and beyond. A few imaging algorithms have been newly proposed by group members, partially completing the existing recommendations, and further important recommendations have been added. The imaging algorithm for prenatally diagnosed hydronephrosis (HN) has been supplemented by a statement on imaging neonates with fetally diagnosed high-grade HN and suspected posterior urethral valves (PUV). Recommendations referring to imaging children with suspected obstructive uropathy, the imaging algorithm for childhood haematuria, and the imaging algorithm for children with suspected urolithiasis have been formulated. The aim was again to reduce invasive and unnecessary investigations wherever possible without running the risk of missing potentially damaging conditions and increasing patient morbidity. As with the existing algorithms, the new proposals are consensus-based recommendations since little Pediatr Radiol (2009) 39:891–898 DOI 10.1007/s00247-009-1233-6

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results